Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI
Abdlemewla Ibrahim, Internist, Former Chief Resident at Haramaya University, shared a post on LinkedIn about a recent article by Elmir Omerovic et al., published in The New England Journal of Medicine, adding:
” Switch-Swedehearth (ClinicalTrials.gov NCT05183178) is a large, pragmatic, registry-based, stepped-wedge cluster-randomized trial that compared a default policy of prasugrel versus ticagrelor as the P2Y12 inhibitor (plus aspirin) after PCI in patients with acute coronary syndrome (ACS).
Nejm
Key design features
- Conducted within the nationwide Swedish Swedehearth registry.
- Seven Swedish regions (grouped into three clusters covering roughly half the country’s population) switched their recommended default P2Y12 inhibitor from ticagrelor to prasugrel in a randomly ordered, staggered fashion across four 9-month periods (May 2021–August 2024).
- Open-label; the final drug choice remained at the treating physician’s discretion.
- Included an unselected, consecutive real-world population of adults undergoing PCI for ACS (including elderly patients, those with prior stroke, and those with an indication for oral anticoagulation—groups often excluded from traditional trials).
- Primary endpoint: composite of death from any cause, myocardial infarction, or stroke at 1 year.
- Secondary endpoint of interest: major bleeding at 1 year.
- News-medical
Main results (17,095 patients)
Ticagrelor-policy group: 9,444 patients (recommended ticagrelor 90 mg twice daily).
Prasugrel-policy group: 7,651 patients (recommended prasugrel 10 mg once daily, reduced to 5 mg in those 75 years or older or less than 60 kg).
Mean age approximately 69.8 years; approximately 28 percent women; substantial proportion 75 years or older.
Primary endpoint (death/MI/stroke at 1 year): 11.1 percent (prasugrel policy) vs 11.8 percent (ticagrelor policy); adjusted OR 0.90 (95 percent CI 0.77–1.06). No significant differences in the individual components (all-cause death, MI, stroke, or stent thrombosis).
Major bleeding at 1 year: lower with the prasugrel policy (4.2 percent vs 4.4 percent; adjusted OR 0.80, 95 percent CI 0.64–0.99).
Escardio
Conclusions and context
A regional default policy of prasugrel did not reduce ischemic events compared with ticagrelor in this broad, unselected ACS-PCI population, but it was associated with a modest reduction in major bleeding (and is generally lower-cost). The trial provides high-quality pragmatic evidence complementing earlier findings (e.g., ISAR-REACT 5) and illustrates the value of registry-embedded randomized trials for answering real-world policy questions efficiently.”
Title: Prasugrel versus Ticagrelor in Acute Coronary Syndromes
Authors: Elmir Omerovic, Sasha Koul, Jonas Andersson, Johan Pontén, Fredrik Björklund, Robert Kastberg, Mila Sun, Charlotta Ljungman, Ole Fröbert, Kristian Bolin, Kristofer Skoglund, Carl-David Dolata, Mats Birgander, Helena Wikström, Truls Råmunddal, Oskar Angerås, Petur Petursson, David Erlinge, Björn Redfors

Stay updated with all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 13:30Stacy E. Croteau: Oral and Dental Care in Pediatric Patients With Bleeding Disorders
-
Nov 17, 2026, 13:19Efe Saglam: Cannabis Use and Cardiac Conduction
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa